A clinical program from the Thoracic Oncology Group of Australasia (TOGA), called ‘ASPiRATION’, which aims to assess the impact of personalised healthcare in lung cancer, has been jointly funded by…
The cluster randomised, crossover, registry-embedded clinical trial of proton pump inhibitors versus histamine-2 receptor blockers for ulcer prophylaxis therapy in the intensive care unit (PEPTIC study) which was posted in JAMA this…
In an article published in the American Journal of Obstetrics & Gynaecology this month, RIDSTRESS, a phase two randomised controlled trial out of the Mater Research Institute in Queensland, has…
This document will assist Clinical Trial Networks in establishing endorsement policies/guidelines….
This event has been cancelled Find out more ANZGOG’s Annual Scientific Meeting (ASM) brings together national and international experts in gynaecological medicine, radiation and surgical oncology, exercise physiologists, quality of…
Award guidelines and nomination form for the ACTA Trial of the Year Award 2020 including the ACTA STInG Excellence in Trial Statistics Award, and the ACTA Consumer Involvement Award. Nominations…
If your network or group published the primary results of a high-impact trial in 2019 (electronically or in print), we encourage you to nominate the trial for the ACTA Trial of the…
ACTA’s Reference Group on Research Prioritisation Tools and Criteria has developed a practical guide and good practice framework for Clinical Trial Networks (CTNs) and other organisations setting priorities for the…
ACTA will soon be inviting all CTNs to participate in an important new survey on CTN Critical Success Factors. The survey will assess the prevalence of success factors, as identified in a recent sector-wide…
We would like to invite Members to join our Special Interest Group for Network managers (SIGNet). ACTA SIGNet provides a forum for Clinical Trial Network (CTN) executive officers, network managers and representatives to…
In 2018, ACTA’s Reference Group on Embedding Clinical Trials in Healthcare produced a report mapping international approaches to embedding clinical trials into the healthcare system. These learnings become increasingly…
Thank you to the ANZICS network and organisers of the 22nd Annual Meeting on Clinical Trials in Intensive Care for inviting ACTA to present on Consumer Involvement in Research. ACTA…
In line with efforts to reduce the spread of COVID-19, the Australian Clinical Trials Alliance (ACTA) has taken proactive steps to move to remote working. In the interests of the…
There has been an array of important advice provided globally and nationally for managing clinical trials in these uncertain times. But synthesizing that information and understanding how to interpret and apply it can…
Part 2: Peak Bodies and TGA Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials, ARCS…
Part 3: Jurisdictions: Federal/States Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials, ARCS is running…
Part 4: Ethics Committees and Governance Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials, ARCS…
Part 5: Role of Clinical Trial Sponsors Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials,…
Part 6: Academics Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials, ARCS is running free…
Part 7: Private Sector Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials, ARCS is running…
Part 8: Pharmacovigilance and Regulatory Affairs Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials, ARCS…
Part 9: Treatment and Prevention Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials, ARCS is…
Part 10: Trial Participants Who should attend: All clinical trial stakeholders, including sites, sponsors and CROs, HREC & governance officers. In response to the risk to clinical trials, ARCS is running…
A joint statement has been released reflecting the shared views of state and territory Departments of Health, the Therapeutic Goods Administration (TGA), National Health and Medical Research Council (NHMRC) and…
The National Medical Health and Research Council (NHMRC) has committed to supporting its Administering Institutions, and the health and medical research sector to address the multiple challenges posed by the COVID-19…
Although the Clinical Trials 2020: National Tribute and Award Ceremony event has been postponed until later in the year, we are keeping nominations open and have extended the closing date to 20…
International and national experts gathered in Melbourne in February for the joint Australasian Lung cancer Trials Group (ALTG) Annual Scientific Meeting and Lung Foundation Australia’s 8th Biennial Australian Lung Cancer…
Because updates are coming in fast, we’ve created this area for all COVID-19 information relevant to clinical trials we have distributed….
We’ve created this area for all COVID-19 information relevant to clinical trials we have gathered. In line with the national guidance and emphasis on the safety and well-being of patients, research participants…
The NSW Office for Health and Medical Research (OHMR) has provided this guidance for sponsors, sites and researchers, for conducting clinical trials affected by the COVID-19 situation. The guidance is…
The Medicine and Healthcare products Regulatory Agency (MHRA) in the UK has released guidance advising those involved in clinical trials on specific issues which may arise as a result of COVID-19….
The US Food and Drug Administration (FDA) has released guidance designed to help industry and investigators navigate the COVID-19 pandemic and help assess how to move forward with critical clinical trials….
ARCS is providing a webinar series on the impact of COVID-19 on clinical trials in Australia. The first webinar, focused on Investigators and Study Coordinators, was held today. ARCS has…
PRAXIS is running a webinar: Managing clinical trials in a time of uncertainty: COVID-19 at 12pm (AEDT) on Wednesday 25 March. You can register here for the PRAXIS open discussion forum, where…
Medical Research Future Fund (MRFF) – Coronavirus research Response Initiative – 2020 Respiratory Medicine Clinical Trials Research on COVID-19 Grant Opportunity is open in Sapphire and will close at 5.00pm (AEST) on…
NHMRC is looking for research and industry experts to assess MRFF 2020 Respiratory Medicine Clinical Trials research on COVID-19 grant opportunity applications – please share your expertise on NHMRC’s online portal….